Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
6 hedge funds and large institutions have $1.18M invested in Soleno Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
5% less capital invested
Capital invested by funds: $1.24M → $1.18M (-$57K)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$181K |
| 2 |
Morgan Stanley
New York
|
+$118K |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$30K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$4.71K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| 5 |
Citigroup
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
1
Bollard Group
Boston,
Massachusetts
| $851K | +$112K | +617 | +13% |
|
|
BIT
2
BlackRock Institutional Trust
San Francisco,
California
| $158K | +$181K | +1,000 | New |
|
|
3
Morgan Stanley
New York
| $103K | +$118K | +652 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $40K | -$89.6K | -495 | -67% |
|
|
VKH
5
Virtu KCG Holdings
New York
| $25K | -$4.71K | -26 | -14% |
|
|
BIM
6
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$30K | -140 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$3K | -16 | Closed |
|
|
9
Citigroup
New York
| – | -$1K | -4 | Closed |
|
SLNO Hedge Fund Activity: Q3 2015 in Review
6 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2015, worth a combined $1.18M — down 4.6% from $1.24M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SLNO and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was BlackRock Institutional Trust, opening a new position worth an estimated $181K. The largest seller was Vanguard Group, cutting an estimated $89.6K.
- 6 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2015, down from 8 in Q2 2015.
- Funds reported $1.18M of Soleno Therapeutics stock for Q3 2015, down 4.6% quarter-over-quarter.
- 2 funds opened new Soleno Therapeutics positions in Q3 2015 and 4 closed out, a net change of -2 holders.
- The largest Soleno Therapeutics buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $181K added.
- The largest Soleno Therapeutics seller in Q3 2015 was Vanguard Group, an estimated $89.6K sold.
Based on aggregated 13F filings for Q3 2015.